<DOC>
	<DOCNO>NCT00095381</DOCNO>
	<brief_summary>BCX-1777 may stop growth cancer cell block enzymes necessary growth . The Phase II trial design study effectiveness BCX-1777 treat patient recurrent refractory advance T-cell leukemia . Patients receive infusion BCX-1777 day 1-5 . Treatment may repeat every week six course . Patients require hospitalized administration BCX-1777 . Some patient may continue receive infusion BCX-1777 twice week 6 week .</brief_summary>
	<brief_title>Repeat-Dose Forodesine Hydrochloride ( BCX-1777 ) Infusion Patients With Advanced T-Cell Leukemia</brief_title>
	<detailed_description>BCX-1777 may stop growth cancer cell block enzymes necessary growth . The Phase II trial design study effectiveness BCX-1777 treat patient recurrent refractory advance T-cell leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<criteria>Documented Tcell leukemia ( precursor Tlymphoblastic leukemia/lymphomia TPLL ) Failure respond one standard regimens disease . Performance status &lt; =2 Eastern Cooperative Oncology Group ( ECOG ) criteria All age eligible Life expectancy least 3 month Adequate liver function ( aspartate transaminase [ AST ] and/or alanine transaminase [ ALT ] &gt; 3 time upper limit normal [ ULN ] ) Adequate kidney function ( calculated creatinine clearance &gt; 50 mL/min ) Negative urine pregnancy test within 2 7 day prior start study treamtment female childbearing potential Females childbearing potential male must willing able use adequate method contraception avoid pregnancy duration study Signed informed consent/assent form ( ICF ) prior start study specific procedure Patients know HIV infection human Tcell leukemia virus type ( HTLV1 ) Patients know Hepatitis B and/or Hepatitis C active infection Patients active CMV infection Tumorrelated central nervous system ( CNS ) leukemia require active treatment Active serious infection control oral IV antibiotic Treatment investigational antileukemic agent chemotherapy agent within 7 day prior study entry , unless full recovery side effect occur . Rapidly progressive disease compromise organ function judge lifethreatening investigator Concurrent treatment anticancer agent ( corticosteroid use exclude , patient must remain stable dose ) Cutaneous Tcell lymphoma ( CTCL ) diagnosis ( include Sezary Syndrome ) Pregnant and/or lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Leukemia , Lymphocytic , T-Cell</keyword>
	<keyword>Entry Term Lymphocytic Leukemia , T-Cell</keyword>
	<keyword>T-Cell Leukemia</keyword>
	<keyword>T-Lymphocytic Leukemia</keyword>
	<keyword>Leukemia , Lymphocytic , T Cell</keyword>
	<keyword>T Lymphocytic Leukemia</keyword>
	<keyword>BCX-1777</keyword>
	<keyword>forodesine hydrochloride</keyword>
	<keyword>BioCryst</keyword>
</DOC>